Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib-induced KIT mutations in gastrointestinal stromal tumours.
第一作者:
Juan,Liu
第一单位:
Anhui Province Key Laboratory of Medical Physics and Technology, CAS Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China.;University of Science and Technology of China, Hefei, China.;Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, China.
作者:
医学主题词
抗肿瘤药(Antineoplastic Agents);抗药性, 肿瘤(Drug Resistance, Neoplasm);胃肠道间质肿瘤(Gastrointestinal Stromal Tumors);人类(Humans);吲哚类(Indoles);突变(Mutation);原癌基因蛋白质类c-kit(Proto-Oncogene Proteins c-kit);嘧啶类(Pyrimidines);增量调节(Up-Regulation)
DOI
10.1002/1878-0261.13199
PMID
35194937
发布时间
2022-07-16
- 浏览0
Molecular oncology
1761-1774页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文


换一批



